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Activins are members of the transforming growth factor β (TGFβ) family and serve
as multifunctional regulatory proteins in many tissues and organs. In the brain,
activin A, which is formed by two disulfide-linked βA subunits, is recognized as the
predominant player in activin signaling. Over the last years, considerable progress
has been made in elucidating novel and unexpected functions of activin in the
normal and diseased brain and in deciphering the underlying molecular mechanisms.
Initially identified as a neurotrophic and protective factor during development and
in several forms of acute injury, the scope of effects of activin A in the adult
central nervous system (CNS) has been considerably broadened by now. Here, we
will highlight recent findings that bear significance for a better understanding of
the pathogenesis of various neuropsychiatric diseases and might hold promise for
novel therapeutic strategies. While the basal level of activin A in the adult brain is
low, significant short-term up-regulation occurs in response to increased neuronal
activity. In fact, brief exposure to an enriched environment (EE) is already sufficient
to considerably strengthen activin signaling. Enhancement of this pathway tunes the
performance of glutamatergic and GABAergic synapses in a fashion that impacts on
cognitive functions and affective behavior, counteracts death-inducing signals through
extrasynaptic NMDA receptors (NMDARs), and stimulates adult neurogenesis in the
hippocampus. We will discuss how impaired activin signaling is involved in anxiety
disorders, depression, drug dependence, and neurodegenerative diseases such as
Alzheimer’s and Parkinson’s, and how reinforcement of activin signaling might be
exploited for therapeutic interventions.
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INTRODUCTION
Activins are members of the transforming growth factor β (TGFβ) family of growth and
differentiation factors. They serve as multifunctional regulatory proteins in many tissues and
organ systems, with particular emphasis on proliferation, differentiation, apoptosis, inflammation,
immunoregulation and repair (Werner and Alzheimer, 2006; Hedger et al., 2011). Structurally,
activins are homo- or heterodimeric proteins containing two disulfide-linked βA (encoded by the
Inhba gene) and/or βB (encoded by the Inhbb gene) subunits. After proteolytic processing of their
precursor proteins, activins are secreted as mature bioactive proteins. Activin A (βA/βA) is the
most abundant and best characterized member of the activin family and plays the predominant
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role in activin signaling in the central nervous system
(CNS). In the developing brain, activin A exerts distinct
neurotrophic effects and is involved in proper cortical layering
and corticostriatal wiring (Andreasson and Worley, 1995).
Importantly, a recent study provided evidence that activin A
supports neuronal differentiation of cortical neuronal progenitor
cells (Rodríguez-Martinez et al., 2012). In the adult brain,
activin A was originally identified as a neuroprotective factor
in various forms of acute brain injury, including stroke (Wu
et al., 1999; Tretter et al., 2000; Mukerji et al., 2009). In
addition to its release from neurons, activin A can be also
of glial origin, as demonstrated in a CNS demyelination
model, where M2 microglia-derived activin A promotes
oligodendrocyte differentiation and remyelination (Miron et al.,
2013). The observation that the expression of activin A is
strongly up-regulated in response to brain lesion and that
both endogenous and recombinant activin A are capable of
affording neuroprotection, led originally to the concept that,
in the adult brain, activin A is a neuroprotective factor that
is called to arms in emergency situations, when an initial
damaging event, such as stroke, threatens to cause a massive
neuronal loss.
Over the last decade, this somewhat narrow view on
the role of activin has been substantially revised and
extended. Our current understanding of the functions of
activin A in the normal and diseased brain encompasses an
astonishingly broad spectrum. On the physiological side of
this range, activin regulates the daily operations of central
synapses in a behaviorally relevant fashion. Major findings
were that: (i) activin enhances cognitive performance by
augmenting synaptic plasticity of excitatory (glutamatergic)
synapses; and that (ii) by tuning inhibitory (GABAergic)
synapses, activin sets the level of anxiety-like behavior.
These findings are testimony to the impact of activin on
mental faculties as well as on affective behavior. Since
the effects of activin on central synapses of the healthy
adult brain and their behavioral consequences have been
reviewed elsewhere (Krieglstein et al., 2011), we will focus
here on the role of activin signaling in neuropsychiatric
disorders.
ACTIVIN SIGNALING
The activin signaling pathway is schematically depicted in
Figure 1. Activins signal through heteromeric complexes of
type II (ActRIIA, ActRIIB) and type I receptors (predominantly
ActRIB, but also ActRIA and ActRIC). Type II receptors bind
activin and recruit type I receptors, which then phosphorylate
the intracellular signaling proteins SMAD2/3. These assemble
with SMAD4, translocate to the nucleus, and bind to specific
target genes to modulate their expression (Chen et al., 2006;
Xia and Schneyer, 2009). It is important to stress that the
strength and duration of activin signaling are tightly controlled
at several nodes along the signaling pathway (Choi and
Han, 2011). In the schematic drawing of Figure 1, negative
regulators of activin signaling are colored in red. Well-known
inhibitors are the secreted proteins follistatin and inhibin,
which preclude activin receptor binding through direct
physical interaction and receptor competition, respectively.
Betaglycan promotes the interaction between inhibin and
ActRII, thereby counteracting activin binding and signaling
(Hedger et al., 2011). In the cell membrane, the pseudoreceptor
BAMBI (BMP and activin membrane-bound inhibitor) inhibits
transmission in a ligand-independent manner. PMEPA1
(prostate transmembrane protein, androgen induced 1) directly
binds to SMAD2/3 and thus prevents their phosphorylation by
activated type I receptors. Notably, PMEPA1 was recently
identified as an activin target gene in the brain (Link
et al., 2015), suggesting that it might serve as a feed-back
inhibitor of activin signaling. The intracellular inhibitor
SMAD7 competitively blocks SMAD2/3 binding sites at type
I receptors. In the nucleus, the transcriptional co-factors
SKI, SKIL and TGIF2 act as transcriptional repressors. In
addition to this canonical signaling pathway, activins can
also activate other pathways, including mitogen-activated
protein kinase (MAPK) signaling (Moustakas and Heldin,
2005).
ACTIVIN SIGNALING IN CONDITIONED
FEAR, ANXIETY, AND DRUG
DEPENDENCE
Although anxiety and fear both describe forms of affective
behavior, which occur in anticipation of threatening stimuli,
be they real or envisioned, it is conceptually helpful to make
a distinction between these terms. We will refer to fear
responses as conditioned behaviors elicited by a particular
cue or environmental context. By contrast, anxiety manifests
itself as a form of behavioral inhibition in conditions of
conflict, when, for example, a novel, but potentially threatening
object or environment requires a choice between approach
vs. avoidance. Conditioned fear has been linked to long-term
synaptic plasticity of glutamatergic synapses in the amygdala
(Pape and Pare, 2010), with the contextual information provided
by the hippocampus. Anxiety-like behavior appears to be
primarily controlled by the (ventral) hippocampus (Bannerman
et al., 2004). As will be detailed in the next section, activin
signaling impinges on both, conditioned fear and anxiety-like
behavior.
Conditioned Fear
Ageta et al. (2010) generated forebrain-specific activin- or
follistatin-transgenic mice in which the transgene expression
was regulated by the Tet-OFF system, allowing temporally
controlled over-expression of activin or its inhibitor follistatin.
If already over-expressed during training in a contextual
fear-conditioning test, follistatin reduced freezing behavior
tested 24 h later. When follistatin or activin were over-
expressed after training, reconsolidation of fear memory
was weakened or strengthened, respectively (Ageta et al.,
2010; Ageta and Tsuchida, 2011). The finding that inhibition
of activin signaling during memory retrieval is capable of
suppressing previously consolidated fear memories is of
particular translational interest, because it advances activin
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FIGURE 1 | Schematic drawing of canonical activin receptor signaling via SMAD2/3 proteins. Note that SMAD2/3 signaling is strictly regulated by
extracellular inhibitors like follistatin and inhibin, transmembrane antagonists such as BAMBI and PMEPA1, the cytoplasmatic inhibitory SMAD7 and several
transcriptional repressors including SKI, SKIL and TGIF2 in the nucleus. All inhibitors are colored in red. For further explanation see text.
signaling as a putative therapeutic target to extinguish
traumatic memories and fear-laden stimuli in human anxiety
disorders such as posttraumatic stress disorder (PTSD) and
phobias.
How does activin signaling interfere with acquisition,
retrieval and extinction of conditioned fear? In view of the
dependence of contextual fear conditioning on synaptic plasticity
in amygdalar and hippocampal circuits, the known effects of
activin signaling on hippocampal long-term potentiation (LTP)
offer a plausible clue. Andreasson and Worley (1995) were
the first to demonstrate up-regulation of activin βA mRNA in
the dentate gyrus (DG) in vivo in response to LTP-inducing
electrical stimulation of the perforant path. Underscoring the
functionality of this up-regulation, later studies found that
forebrain-specific disruption of activin receptor signaling and
over-expression of follistatin impaired LTP in area CA1 and
DG (Muller et al., 2006; Ageta et al., 2010). Mechanistically,
activin augments LTP by targeting several of its essential
mechanisms, including NMDA receptor (NMDAR) currents
and spine density and morphology (Muller et al., 2006;
Shoji-Kasai et al., 2007; Kurisaki et al., 2008; Hasegawa et al.,
2014).
Anxiety, Alcohol and GABAA Receptors
Transgenic mice expressing a dominant-negative ActRIB in
forebrain neurons display a low-anxiety phenotype in typical
conflict paradigms in which the innate drive to explore a
novel environment is opposed by the tendency to stay in safe
surroundings (Zheng et al., 2009). The decrease in anxiety-
like behavior in these mice has been linked to concomitant
alterations in GABAergic inhibition, based on a number of
conspicuous parallels: (i) Tonic inhibition by extrasynaptic
GABAA receptors (GABAARs), which is thought to exert
anxiolytic effects (Brickley andMody, 2012;Whissell et al., 2015),
is enhanced in the mutant mice; (ii) GABAARs of the mutant
mice show substantially less sensitivity to diazepam, concomitant
with a loss of the anxiolytic drug effect at the behavioral level;
and (iii) GABABR function is augmented in the transgenic mice,
consistent with reports that positive GABABRmodulators reduce
anxiety-like behavior (Zheng et al., 2009).
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Given that disruption of activin receptor signaling reduces
allosteric modulation of GABAARs by diazepam, it came as
a surprise that ethanol potentiation of GABAAR-mediated
inhibitory synaptic transmission was enhanced in the same
transgenic mice (Zheng et al., 2015). As a consequence, low
concentrations of ethanol (≤30 mM) are now capable of
potentiating the inhibitory effects of synaptic GABAARs. Loss of
neuronal activin receptor signaling renders not only GABAARs
more sensitive to ethanol, but also produces significantly stronger
sedation at the behavioral level (Zheng et al., 2015). These data
suggest that activin regulates behavioral effects of ethanol by
controlling ethanol potentiation of GABAAR function, arguably
the pre-eminent target of ethanol in the brain. At the molecular
level, activin appears to adjust ethanol sensitivity of GABAARs
through a non-canonical, i.e., SMAD2/3-independent signaling
pathway involving PKCε (Zheng et al., 2015). Notably, this PKC
isoform has been previously shown to regulate the responsiveness
of GABAARs to ethanol (Hodge et al., 1999).
Cocaine Craving
While activin is involved in the sedating, but not in the
reinforcing effects of ethanol (Zheng et al., 2015), a recent
study implicated activin signaling in maladaptive processes
leading to drug craving and relapse after cocaine withdrawal
(Gancarz et al., 2015). After 7 days, but not after 1 day
of withdrawal following cocaine self-administration in rats,
phosphorylation of SMAD3 was specifically increased in
the shell of the nucleus accumbens (NAc). Intra-accumbal
microinjection of activin A increased drug self-administration,
whereas viral over-expression of a dominant-negative mutant
of SMAD3 (dnSMAD3) in the NAc had the opposite effect.
Moreover, dnSMAD3 abrogated the increase in the density
of dendritic spines on medium spiny neurons in the NAc,
which typically accompanies drug-induced reinstatement of
cocaine self-administration (Gancarz et al., 2015). Such structural
plasticity following withdrawal is considered essential for the
endurance of cocaine-seeking behavior, and activin signaling
appears to be a driving force behind this rewiring process. As
pointed out earlier, changes in spine morphology have been
also proposed as a mechanism through which activin promotes
hippocampal LTP and memory formation. This leaves us with
the intriguing idea that, depending on whether it is recruited
endogenously (e.g., by learning processes in the hippocampus)
or hijacked exogenously (e.g., by drugs of abuse in the NAc),
activin signaling can operate both ways, increasing cognitive
performance as well as instituting drug-seeking behavior and
relapse.
ACTIVIN SIGNALING AND DEPRESSION
Activin Signaling as a Target in
Antidepressant Treatment
Given the co-morbidity of mood and anxiety disorders,
it should not come unexpected that activin signaling has
also been assigned a role in depression. Specifically, several
proteins of the activin signaling pathway were found to be
up-regulated in rodent brain after chronic administration
of clinically used antidepressants. Chronic and subchronic
paroxetine produced an increased expression of Inhba mRNA
and of ActRIA mRNA in circumscribed regions of mouse
hippocampus (Ganea et al., 2012). While not influencing Inhba
expression, chronic fluoxetine and desipramine did increase
SMAD2 phosphorylation in rat frontal cortex (Dow et al., 2005).
Furthermore, genetic polymorphism in TGFBR3 which codes
for betaglycan, a functional inhibitor of activin binding and
signaling (v.s.), has been associated with the clinical response
to antidepressant drugs (Ganea et al., 2012). Electroconvulsive
therapy (ECT), the second mainstay of antidepressant treatment,
engenders a strong and rapid (within 2 h) increase of Inhba
mRNA in hippocampus, amygdala and several neocortical
areas, followed by enhanced SMAD2 phosphorylation, indicating
subsequent activation of the canonical activin signaling pathway
in this rodent model of ECT (Dow et al., 2005; Link et al., 2015).
Compared to other members of the TGFβ family, which also
signal via SMAD2/3, only Inhba expression was significantly
increased, strongly suggesting that ECT gives rise exclusively
to activin A protein (Link et al., 2015). Taken by themselves,
these findings do not necessarily indicate a role of activin
as a mediator of the therapeutic effects of antidepressant drugs
or ECT. It was therefore reassuring that stereotactic infusion
of recombinant activin A into rat and mouse hippocampus
produced antidepressant-like effects in the forced swim test,
a behavioral model of depression (Dow et al., 2005; Ganea
et al., 2012). Notably, the antidepressant-like effects were only
observed when activin A was injected into the DG, but not when
injected into the CA1 region or into the amygdala (Dow et al.,
2005; Ganea et al., 2012).
Activin, Depression, Adult Neurogenesis
and Epigenetic Modification
The DG clearly emerges as the essential brain region linking
activin signaling to its antidepressant effects. In view of the
(not undisputed) neurogenic hypothesis of depression, which
posits that adult-generated neurons of the DG are required for
balanced mood and antidepressant efficacy (Eisch and Petrik,
2012), an obvious question is whether the therapeutic effects of
activin can be causally related to increased adult neurogenesis.
Whereas it remains controversial whether the basal level of
endogenous activin in the intact adult brain is sufficient to
influence baseline neurogenesis, administration of activin A to
the normal hippocampus did enhance neural stem/precursor
cell proliferation (Ageta et al., 2008; Abdipranoto-Cowley et al.,
2009). These findings would be consistent with the concept
that the dramatic up-regulation of activin by antidepressant
treatment contributes to disease remission by promoting
hippocampal neurogenesis.
With the identification of the histone demethylase KDM6B
as the product of an activin target gene in the brain, epigenetic
regulation might emerge as a new effect of activin signaling
that could contribute to its antidepressant effects (Link et al.,
2015). According to this hypothesis, enhanced activin signaling
following ECT or antidepressant pharmacotherapy would lead to
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FIGURE 2 | Schematic model of how environmental enrichment (EE)
and electroconvulsive therapy (ECT) may produce epigenetic
modification through enhanced activin signaling and transcription of
the activin target gene Kdm6b. KDM6B acts as a histone demethylase
thereby promoting gene expression of transcriptionally repressed genes.
Background: in situ hybridization of coronal mouse brain section showing
pronounced increase in Inhba mRNA level in dentate gyrus (DG) 2 h after
ECT-like electrical stimulation.
chromatin remodeling and increased transcriptional activity as
schematically depicted in Figure 2.
Finally, activin A might also serve as an endogenous
antidepressant in its own right, independent of its up-regulation
by antidepressant treatment. Strong support for this notion
comes from experiments with mice placed into an enriched
environment (EE). Compared to mice housed in standard cages,
EE exposure produced a marked up-regulation of Inhba mRNA
in the DG and the CA3 region of the hippocampus, accompanied
by increased SMAD2/3 phosphorylation (Link et al., 2015).
These findings suggest that the mood-elevating and cognition-
enhancing effects attributed to EE might be mediated, at least in
part, by enhanced activin signaling.
ACTIVIN AND NEURODEGENERATIVE
DISEASES
In an excitotoxic rodent model of Huntington’s disease,
intrastriatal administration of recombinant activin A for 1 week
rescued striatal interneurons and projection neurons from
death (Hughes et al., 1999). Administration of recombinant
activin A also protected dopaminergic midbrain neurons against
MPP+-induced cell death in vitro (Krieglstein et al., 1995) and
in the 6-OHDA mouse model of Parkinson’s disease (Stayte
et al., 2015). While these studies suggest that activin signaling
might be targeted to fight off gradual neuronal demise in
chronic neurodegenerative disease, the underlying mechanism
had been elusive until recently. A widely held concept posits
that a proper balance between signals transmitted by synaptic
vs. extrasynaptic NMDARs is an essential determinant of
neuronal integrity (Hardingham and Bading, 2010). Activation
of synaptic NMDARs triggers synaptic plasticity and fosters
genetic programs for stress resilience and survival. By
contrast, activation of extrasynaptic NMDARs can incur
lethal consequences for neurons, as it initiates pro-apoptotic
pathways. Lau et al. (2015) have now revealed an intriguing
interplay between brain-derived neurotrophic factor (BDNF)
and activin signaling that is instrumental to shift the delicate
balance between extrasynaptic and synaptic NMDARs in
favor of the latter, thereby strengthening neuronal health
and long-term survival. In brief, this survival-promoting
scheme comprises the following sequence of events. Activity-
dependent increase in Bdnf transcription or administration of
exogenous BDNF promotes activation of synaptic NMDARs,
thereby inducing nuclear calcium signaling, which in turn
activates transcription of Inhba. Secreted activin A then reduces
potentially neurotoxic Ca2+ influx through extrasynaptic
NMDARs, thereby counteracting pro-death pathways (Lau et al.,
2015). Based on such a scenario, it seems plausible to assume
that any perturbation of the neuroprotective interaction between
BDNF and activin A should render neurons more vulnerable
to excitotoxic damage and might thus represent an important
pathogenetic factor in protracted neurodegenerative diseases
such as Huntington’s, Parkinson’s or Alzheimer’s.
OUTLOOK
The characterization of Inhba as a BDNF-induced gene
and the identification of the sequential and interdependent
activation of BNDF and activin signaling as a health-promoting
mechanism offer an intriguing new perspective on possibly
shared functions of these two factors that might well go
beyond their involvement in combating neuronal loss in
neurodegenerative diseases. A quick review of the multiple roles
of BDNF in the adult brain reveals a broad spectrum of effects
that show a striking overlap with those of activin. Like activin,
BDNF has been implicated in activity-dependent regulation of
synaptic plasticity (Minichiello, 2009; Edelmann et al., 2014).
In fact, the effects of BDNF bear a strong resemblance with
those of activin in that both factors alter key morphological
and electrophysiological features of glutamatergic synapses,
thereby providing a double underpinning for neuronal processes
intimately involved in learning and memory. Moreover,
several lines of evidence show that BDNF, like activin,
crucially modulates the strength of GABAergic inhibition
(Gottmann et al., 2009). In addition to their involvement
in anxiety disorders (Liu et al., 2004; Martinowich et al.,
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2007) and drug addiction (Li and Wolf, 2015), activin and
BDNF appear to be endowed with antidepressant efficacy
(Martinowich et al., 2007). Both signaling pathways are
stimulated by EE and, much more so, by ECT, as well as
by antidepressant drug treatment (Nibuya et al., 1995; Link
et al., 2015). With BDNF and activin being up-regulated
strongest in the DG, both factors were found to stimulate
adult neurogenesis, which is thought to support remission
of depression (Martinowich et al., 2007). Thus, several lines
of evidence indicate that BDNF and activin synergistically
co-regulate neuronal responses, suggesting essential cross-talk of
their signaling pathways.
In contrast to BDNF, which has long since taken center
stage as a master regulator of various neuronal properties
and functions during development and in adulthood, the
multiple roles of activin are only gradually being uncovered.
It seems that, in many aspects, activin and BDNF are two
players with very similar overall targets, which join forces
in neuroprotection, synaptic plasticity and neuropsychiatric
diseases. The commonalities and differences in the strategies
these two factors pursue to achieve these goals and the extent
to which the underlying mechanisms are complementary and
interdependent should be exciting topics for future research.
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